Fosun Pharma Industrial Pte. Limited, Singapore
Case brief
What is this about?
The Competition Commission of India approved a proposed combination involving the acquisition of Gland Pharma's equity and convertible preference shares by Fosun Singapore. The Commission analyzed relevant product markets, competitive constraints, and market shares.
What did the court decide?
Approval granted under Section 31(1) of the Competition Act, 2002. Order subject to conditions regarding confidentiality and information accuracy.
What the court decided
A compact analysis
This page shows the compact analysis of this judgement. The full analysis — procedural history, issue-by-issue holdings with ratio and obiter, advocates, and paragraph-level evidence for every claim — is being added to the record in batches and will appear here when this judgement has been through it.
Fair Competition For Greater Good
COMPETITION COMMISSION OF INDIA
(Combination Registration No.C-2016/08/425)
13th December 2016
Notice under Section 6 (2) of the Competition Act, 2002 filed by Fosum Pharma Industrial PTE Limited
CORAM
Devender Kumar Sikri
Chairperson
S.L. Bunker
Member
Sudhir Mital
Member
Augustine Peter
Issues for consideration
2 issues framed by the court
Whether the proposed combination involves acquired equity shares and compulsory convertible preference shares in Gland Pharma raises concerns of appreciable adverse effect on competition.
Whether the proposed combination was likely to have appreciable adverse effect on competition in the relevant markets for Heparin Sodium API/Clindamycin APIs.
Parties & counsel
- other
Competitors in the Pharmaceutical Sector
Coram
Devender Kumar Sikri
S.L. Bunker
Sudhir Mital
Case details
As recorded by the court registry
Similar cases
Judgements on the same questions, provisions and authorities, from every court